Tumor-specific cytolysis by lymphocytes infiltrating human melanomas

Suzanne Topalian, D. Solomon, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Tumor infiltrating lymphocytes (TIL) were grown in IL-2 from single cell tumor suspensions of 14 human melanomas resected from 12 patients. As a function of time in culture, 4 of 14 TIL cultures eventually expressed highly specific cytolytic activity against fresh autologous melanoma targets in short term chromium release assays, failing to lyse multiple allogeneic tumors or autologous normal cells. These highly specific TIL were identified as CTL by phenotype (CD3+/CD4-/CD8+/Leu-7-) and by function (lysis inhibited by antibodies directed against CD3 and MHC class I molecules). Cell separation experiments using immunomagnetic beads identified a highly tumor-specific CTL subpopulation within a nonspecific TIL culture, suggesting that the lytic activity of tumor-specific CTL may be diluted by the nonspecific killer activity present in heterogeneous TIL cultures. These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.

Original languageEnglish (US)
Pages (from-to)3714-3725
Number of pages12
JournalJournal of Immunology
Volume142
Issue number10
StatePublished - 1989
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Melanoma
Lymphocytes
Neoplasms
Cell Separation
Chromium
Immunotherapy
Interleukin-2
Suspensions
Clinical Trials
Phenotype
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. / Topalian, Suzanne; Solomon, D.; Rosenberg, S. A.

In: Journal of Immunology, Vol. 142, No. 10, 1989, p. 3714-3725.

Research output: Contribution to journalArticle

Topalian, S, Solomon, D & Rosenberg, SA 1989, 'Tumor-specific cytolysis by lymphocytes infiltrating human melanomas', Journal of Immunology, vol. 142, no. 10, pp. 3714-3725.
Topalian, Suzanne ; Solomon, D. ; Rosenberg, S. A. / Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. In: Journal of Immunology. 1989 ; Vol. 142, No. 10. pp. 3714-3725.
@article{0407ac3c1533400d9d34a494b8f4d84b,
title = "Tumor-specific cytolysis by lymphocytes infiltrating human melanomas",
abstract = "Tumor infiltrating lymphocytes (TIL) were grown in IL-2 from single cell tumor suspensions of 14 human melanomas resected from 12 patients. As a function of time in culture, 4 of 14 TIL cultures eventually expressed highly specific cytolytic activity against fresh autologous melanoma targets in short term chromium release assays, failing to lyse multiple allogeneic tumors or autologous normal cells. These highly specific TIL were identified as CTL by phenotype (CD3+/CD4-/CD8+/Leu-7-) and by function (lysis inhibited by antibodies directed against CD3 and MHC class I molecules). Cell separation experiments using immunomagnetic beads identified a highly tumor-specific CTL subpopulation within a nonspecific TIL culture, suggesting that the lytic activity of tumor-specific CTL may be diluted by the nonspecific killer activity present in heterogeneous TIL cultures. These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.",
author = "Suzanne Topalian and D. Solomon and Rosenberg, {S. A.}",
year = "1989",
language = "English (US)",
volume = "142",
pages = "3714--3725",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Tumor-specific cytolysis by lymphocytes infiltrating human melanomas

AU - Topalian, Suzanne

AU - Solomon, D.

AU - Rosenberg, S. A.

PY - 1989

Y1 - 1989

N2 - Tumor infiltrating lymphocytes (TIL) were grown in IL-2 from single cell tumor suspensions of 14 human melanomas resected from 12 patients. As a function of time in culture, 4 of 14 TIL cultures eventually expressed highly specific cytolytic activity against fresh autologous melanoma targets in short term chromium release assays, failing to lyse multiple allogeneic tumors or autologous normal cells. These highly specific TIL were identified as CTL by phenotype (CD3+/CD4-/CD8+/Leu-7-) and by function (lysis inhibited by antibodies directed against CD3 and MHC class I molecules). Cell separation experiments using immunomagnetic beads identified a highly tumor-specific CTL subpopulation within a nonspecific TIL culture, suggesting that the lytic activity of tumor-specific CTL may be diluted by the nonspecific killer activity present in heterogeneous TIL cultures. These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.

AB - Tumor infiltrating lymphocytes (TIL) were grown in IL-2 from single cell tumor suspensions of 14 human melanomas resected from 12 patients. As a function of time in culture, 4 of 14 TIL cultures eventually expressed highly specific cytolytic activity against fresh autologous melanoma targets in short term chromium release assays, failing to lyse multiple allogeneic tumors or autologous normal cells. These highly specific TIL were identified as CTL by phenotype (CD3+/CD4-/CD8+/Leu-7-) and by function (lysis inhibited by antibodies directed against CD3 and MHC class I molecules). Cell separation experiments using immunomagnetic beads identified a highly tumor-specific CTL subpopulation within a nonspecific TIL culture, suggesting that the lytic activity of tumor-specific CTL may be diluted by the nonspecific killer activity present in heterogeneous TIL cultures. These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0024390061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024390061&partnerID=8YFLogxK

M3 - Article

C2 - 2785562

AN - SCOPUS:0024390061

VL - 142

SP - 3714

EP - 3725

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -